NDLI: Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling

Content Provider	Springer Nature Link
Author	Kacevska, Marina Mahns, Andre Sharma, Rohini Clarke, Stephen J. Robertson, Graham R. Liddle, Christopher
Copyright Year	2013
Abstract	In many cancer patients, the malignancy causes reduced hepatic drug clearance leading to potentially serious complications from the use of anticancer drugs. The mechanisms underlying this phenomenon are poorly understood. We aimed to identify tumor-associated inflammatory pathways that alter drug response and enhance chemotherapy-associated toxicity.We studied inflammatory pathways involved in extra-hepatic tumor mediated repression of CYP3A, a major hepatic drug metabolizing cytochrome P450 subfamily, using a murine Engelbreth-Holm-Swarm sarcoma model. Studies in IL-6 knockout mice determined the source of elevated IL-6 in tumor-bearing animals and monoclonal antibodies against IL-6 were used to intervene in this inflammatory pathway.Our studies confirm elevated plasma IL-6 levels and reveal activation of Jak/Stat and Mapk signalling pathways and acute phase proteins in livers of tumor-bearing mice. Circulating IL-6 was predominantly produced by the tumor xenograft, rather than being host derived. Anti IL-6 antibody intervention partially reversed tumor-mediated inflammation and Cyp3a gene repression.IL-6 is an important player in cancer-related repression of CYP3A-mediated drug metabolism and activation of the acute phase response. Targeting IL-6 in cancer patients may prove an effective approach to alleviating cancer-related phenomena, such as adverse drug-related outcomes commonly associated with cancer chemotherapy.
Starting Page	2270
Ending Page	2278
Page Count	9
File Format	PDF
ISSN	07248741
Journal	Pharmaceutical Research
Volume Number	30
Issue Number	9
e-ISSN	1573904X
Language	English
Publisher	Springer US
Publisher Date	2013-04-20
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	cancer cancer chemotherapy CYP3A drug metabolism inflammation interleukin-6 Pharmacology/Toxicology Pharmacy Biochemistry Medical Law Biomedical Engineering
Content Type	Text
Resource Type	Article
Subject	Organic Chemistry Pharmacology Molecular Medicine Pharmacology (medical) Biotechnology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Down-Regulation of Hepatic CYP3A in Chronic Renal Insufficiency

Hepatic CYP3A Expression is Attenuated in Obese Mice Fed a High-Fat Diet

Extrahepatic Ischemia-Reperfusion Injury Reduces Hepatic Oxidative Drug Metabolism as Determined by Serial Antipyrine Clearance

Interleukin-1 Receptor (IL-1R) Liquid Formulation Development Using Differential Scanning Calorimetry

Disease, Drug Metabolism, and Transporter Interactions

Mitochondrial Metabolism Inhibitors for Cancer Therapy

Isolation and Characterization of an Acetylated Impurity in Escherichia coli-Derived Recombinant Human Interleukin-10 (IL-10) Drug Substance

Delivered Dose: A Drug-centric Phenotype for Chemotherapy Dose Individualization

Drug Delivery Using Platelet Cancer Cell Interaction

Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling

Similar Documents

Down-Regulation of Hepatic CYP3A in Chronic Renal Insufficiency

Hepatic CYP3A Expression is Attenuated in Obese Mice Fed a High-Fat Diet

Extrahepatic Ischemia-Reperfusion Injury Reduces Hepatic Oxidative Drug Metabolism as Determined by Serial Antipyrine Clearance

Interleukin-1 Receptor (IL-1R) Liquid Formulation Development Using Differential Scanning Calorimetry

Disease, Drug Metabolism, and Transporter Interactions

Mitochondrial Metabolism Inhibitors for Cancer Therapy

Isolation and Characterization of an Acetylated Impurity in Escherichia coli-Derived Recombinant Human Interleukin-10 (IL-10) Drug Substance

Delivered Dose: A Drug-centric Phenotype for Chemotherapy Dose Individualization

Drug Delivery Using Platelet Cancer Cell Interaction

Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling